PYVAX Performance — Payden Equity Income Fund, (Advisor Class)
Data updated: 2026-09-23
PYVAX returned +12.10% year to date and +19.57% over one year to Jul 2026. Annualised returns are +14.33% over 3 years and +8.42% over 5 years. The fund trailed its US Large Value category average: $100 invested three years ago grew to $149, against $156 for the category, and to $120 over one year, against $122. Volatility over the past three years was 11.49% a year. In the 12 months to Jul 2026 the fund lost a net $49.8M, and assets reached $1.11B.
PYVAX Growth of $100
What $100 invested in Payden Equity Income Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Large Value category average over the same months.
| Period | PYVAX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $120 | $122 |
| 3 years (Aug 2023 – Jul 2026) | $149 | $156 |
| 5 years (Aug 2021 – Jul 2026) | $150 | $168 |
| Since data start (Aug 2019 – Jul 2026) | $186 | $226 |
PYVAX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +12.10% |
| 1 year | +19.57% |
| 3 years (annualised) | +14.33% |
| 5 years (annualised) | +8.42% |
PYVAX Annual Returns
Calendar-year total returns of Payden Equity Income Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +12.10% |
| 2025 | +11.18% |
| 2024 | +15.71% |
| 2023 | +5.00% |
| 2022 | −6.95% |
| 2021 | +22.96% |
| 2020 | +0.56% |
| 2019 (Aug–Dec) | +6.93% |
PYVAX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.4% | +2.4% | −4.0% | +6.8% | +1.8% | +0.4% | +2.1% | — | — | — | — | — |
| 2025 | +4.0% | −0.4% | −4.9% | −2.3% | +4.3% | +3.3% | +0.4% | +2.2% | +1.8% | +0.9% | +2.0% | −0.4% |
| 2024 | +1.2% | +4.1% | +3.4% | −3.8% | +4.1% | 0.0% | +3.3% | +2.1% | +1.3% | −1.0% | +6.6% | −6.0% |
| 2023 | +1.4% | −3.8% | −0.9% | +1.3% | −3.8% | +5.0% | +2.5% | −1.7% | −3.9% | −2.8% | +7.3% | +5.0% |
| 2022 | −2.1% | −2.0% | +3.9% | −4.6% | +1.7% | −7.4% | +5.1% | −2.3% | −7.4% | +9.5% | +5.1% | −5.0% |
| 2021 | −0.6% | +4.0% | +5.1% | +3.1% | +3.0% | −0.5% | +0.8% | +2.0% | −3.8% | +5.0% | −2.9% | +6.2% |
| 2020 | −0.5% | −9.6% | −12.7% | +9.7% | +2.7% | −0.9% | +3.0% | +3.1% | −2.5% | −2.3% | +10.0% | +3.0% |
| 2019 | — | — | — | — | — | — | — | −0.1% | +2.1% | +0.7% | +1.2% | +2.9% |
PYVAX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 11.49%
- 3-year Sharpe ratio: 0.86 (vs 4.5% risk-free rate)
- Best month: +7.35% (Nov 2023)
- Worst month: −6.01% (Dec 2024)
PYVAX Fund Flows
Monthly money in and out of Payden Equity Income Fund, from SEC Form N-PORT.
- 12-month net flow: −$49.8M
- 12-month gross sales (incl. reinvestments): $103.4M
- Sales ÷ redemptions: 0.67×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $1.6M | $5.1M | −$3.4M |
| Jun 2026 | $6.3M | $11.2M | −$4.9M |
| May 2026 | $4.6M | $2.1M | $2.5M |
| Apr 2026 | $5.0M | $3.6M | $1.4M |
| Mar 2026 | $4.4M | $25.5M | −$21.1M |
| Feb 2026 | $6.8M | $4.8M | $2.0M |
| Jan 2026 | $5.7M | $2.1M | $3.6M |
| Dec 2025 | $54.4M | $12.6M | $41.8M |
| Nov 2025 | $1.8M | $64.1M | −$62.3M |
| Oct 2025 | $5.3M | $5.2M | $139K |
| Sep 2025 | $6.7M | $6.1M | $577K |
| Aug 2025 | $822K | $11.0M | −$10.2M |
PYVAX Assets Under Management
Net assets of Payden Equity Income Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $1.11B |
| 2026-04-30 | $1.07B |
| 2026-01-30 | $1.04B |
| 2025-10-31 | $1.07B |
| 2025-07-31 | $1.03B |
| 2025-04-30 | $963.65M |
| 2025-01-31 | $1.03B |
| 2024-10-31 | $1.06B |
| 2024-07-31 | $1.07B |
| 2024-04-30 | $1.24B |
| 2024-01-31 | $1.25B |
| 2023-10-31 | $1.14B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.